Literature DB >> 15307047

Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation.

C M El Saleeby1, J Suzich, M E Conley, J P DeVincenzo.   

Abstract

A patient with respiratory syncytial virus (RSV) infection and severe combined immunodeficiency was studied during a 3-month period of bone marrow transplantation and palivizumab infusion. No RSV isolates with palivizumab escape mutations were identified. Donor lymphocytes, including CD8 cells, appeared to markedly reduce the RSV load but increased the pulmonary symptoms. Immunosuppressive therapy ameliorated lung disease but allowed the RSV load to rebound.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15307047     DOI： 10.1086/421779

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

1.  Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics.

Authors:  Jessica W Lau; Young-In Kim; Ryan Murphy; Ruchi Newman; Xiao Yang; Michael Zody; John DeVincenzo; Yonatan H Grad
Journal:  Virology       Date:  2017-08-03       Impact factor: 3.616

2.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Identification of Novel Respiratory Syncytial Virus CD4+ and CD8+ T Cell Epitopes in C57BL/6 Mice.

Authors:  Megan E Schmidt; Steven M Varga
Journal:  Immunohorizons       Date:  2019-01-14

5.  In vivo selection of respiratory syncytial viruses resistant to palivizumab.

Authors:  Xiaodong Zhao; Wayne M Sullender
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 6.  Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Authors:  Barney S Graham
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  CD8+ T-cell epitope mapping for pneumonia virus of mice in H-2b mice.

Authors:  Kevin B Walsh; John Sidney; Megan Welch; Daniel M Fremgen; Alessandro Sette; Michael B A Oldstone
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

8.  Role of T cells in virus control and disease after infection with pneumonia virus of mice.

Authors:  Stefanie Frey; Christine D Krempl; Annette Schmitt-Gräff; Stephan Ehl
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

10.  Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure.

Authors:  Yonatan H Grad; Ruchi Newman; Michael Zody; Xiao Yang; Ryan Murphy; James Qu; Christine M Malboeuf; Joshua Z Levin; Marc Lipsitch; John DeVincenzo
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.